A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

I4D-MC-JTJN -

The purpose of this study is to evaluate the efficacy and safety of prexasertib in women with ovarian, primary peritoneal, or fallopian tube cancer that did not respond well to chemotherapy or has recurred.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Ovarian Cancer
What the trial is testing?
Prexasertib
Could I receive a Placebo?
No
Enrollment Goal
172
Trial Dates
Apr 10, 2018 - Oct 3, 2020
How long will I be in the trial?
Your participation depends on how well your disease responds to the study treatment and how many cycles of treatment you receive. One cycle is 28 days.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have advanced ovarian, primary peritoneal or fallopian tube cancer

  • Participants must have cancer that did not respond well to chemotherapy and must have had the breast cancer gene test

  • Participants must have adequate organ function

  • Participants must be able and willing to undergo tumor biopsy before treatment

Participants Must Not:

  • Participants must not have known central nervous system (CNS) cancer or cancer that has spread to the CNS

  • Participants must not have a history of any of the following:

    • Abdominal fistula (abnormal opening between the stomach or intestines and the skin) or gastrointestinal perforation (hole in the stomach or intestines)

    • Abdominal abscess (collection of fluid and puss inside the abdomen) within last 3 months

    • Bowel blockage within the last 3 months

  • Participants must not have symptoms of active HIV infection or hepatitis A, B, or C

  • Participants must not have a serious heart condition

  • Participants must not have received radiation to the whole pelvis

  • Participants must not take corticosteroids daily (with the exception of inhaled steroids)

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.